SI
BHVN

Symmetry Investments’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Symmetry Investments’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,500
Closed -$1.07M – 110
2020
Q4 		$1.07M Buy
+12,500
New +$1.06M 0.3% 45

Other funds holding BHVN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Symmetry Investments's BHVN Position: Q2 2022 in Review

Symmetry Investments sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 10,000 shares — an estimated $1.19M sold.

Symmetry Investments first reported a position in BHVN in Q1 2021 and held it in 4 quarters. The position peaked at $3.08M in Q1 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Symmetry Investments reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Symmetry Investments sold 10,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $1.19M.
  • Symmetry Investments first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 4 quarters.
  • Symmetry Investments's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.08M in Q1 2021.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Symmetry Investments's 13F filing for Q2 2022, filed 26 Jul 2022.